TTrialPathMatch Me to Trials
← Back to trials
RecruitingType 2 Diabetes

Liver Fat as a Dietary Target of the Chinese Medical Nutrition Therapy (CMNT) Diet for Treating Type 2 Diabetes With Nonalcoholic Fatty Liver Disease

Eligible age

18–75 yrs

Accepts

All genders

Locations

0 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Type 2 diabetes (T2D) represents a serious public health problem. Patients with T2D and non-alcoholic fatty liver disease(NAFLD) demonstrate a poor metabolic profile and increase mortality compared with patients with only NAFLD or T2D. Nutritional intervention is the most basic treatment for T2D. Previous study showed that a Chinese medical nutrition therapy (CMNT) diet, which intermittent use of low-calorie medicinal food, has a glucose-lowering effect in T2D. This study aims to investigate the effect of a Chinese medical nutrition therapy (CMNT) diet accompanied by intermittent energy restriction on reducing liver fat and glycated hemoglobin (HbA1c) in patients with T2D and NAFLD.

Sponsor: State Key Laboratory of Subhealth Intervention Technology

You may qualify if…

  • ✓ Patients diagnosed with type 2 diabetes and NAFLD
  • ✓ Age between 18 and 75 years
  • ✓ BMI between 18.0 and 35.0 kg/m2
  • ✓ Weight stable for at least 3 months prior to the study (gain or loss \< 4 kg)
  • ✓ Stable treatment for at least 3 months with 1-3 oral antidiabetic medications (with or without insulin therapy), or not yet received antidiabetic medication prior to the beginning of the study
  • ✓ Able to give written informed consent

You may not qualify if…

  • ✕ Self-reported a food allergy
  • ✕ Alcohol abuse in the last 3 months (alcohol intake greater than 20 g per day for women; Alcohol intake for men greater than 40 g per day)
  • ✕ Other liver diseases such as chronic hepatitis B and C, autoimmune hepatitis, primary biliary cirrhosis, hemochromatosis, nodular regenerative hyperplasia and focal nodular hyperplasia
  • ✕ Scheduled to be hospitalized for any surgical treatment during screening
  • ✕ Pregnant or planning of pregnancy during the study
  • ✕ Inability, physically or mentally, to adhere the procedures required by the study protocol
  • ✕ Level 3 hypoglycemic events (at least 3 times) occurring within the 90 days prior to screening
  • ✕ Hospitalization or emergency department visit for hyperglycemia, diabetic ketoacidosis, lactic acidosis, hyperosmolar nonketotic coma, or diabetes

Source: ClinicalTrials.gov · NCT05439226 · last updated 2025-07-25

Liver Fat as a Dietary Target of the Chinese Medical Nutrition Therapy · TrialPath